Radiopharm Theranostics L... (RADX)
NASDAQ: RADX
· Real-Time Price · USD
3.90
-0.08 (-2.01%)
At close: Apr 28, 2025, 2:28 PM
-2.01% (1D)
| Bid | 4.15 |
| Market Cap | 101.14K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -11.88 |
| PE Ratio (ttm) | -0.33 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.36 |
| Volume | 5,519 |
| Avg. Volume (20D) | 188,286 |
| Open | 4.00 |
| Previous Close | 3.98 |
| Day's Range | 3.87 - 4.00 |
| 52-Week Range | 3.50 - 50.82 |
| Beta | 0.87 |
About RADX
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical target...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 5, 2024
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol RADX
Advertisement
Analyst Forecast
According to 1 analyst ratings, the average rating for RADX stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 284.62% from the latest price.
Stock Forecasts2 months ago
-4.29%
Radiopharm Theranostics shares are trading higher ...
Unlock content with
Pro Subscription
3 months ago
+32.75%
Radiopharm Theranostics shares are trading higher after the company announced it will execute a private placement and will raise $5 million in proceeds.